Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 5 of 5 entries
Sorted by: Best Match Show Resources per page
Assessment of annoyance due to urban road traffic noise combined with tramway noise.

The Journal of the Acoustical Society of America

Klein A, Marquis-Favre C, Champelovier P.
PMID: 28147615
J Acoust Soc Am. 2017 Jan;141(1):231. doi: 10.1121/1.4973518.

Due to the expansion of urban areas, an increasing number of residents are exposed to combined community noise sources. Studies show that the exposure to transportation noise significantly affects health and well-being. Noise annoyance is one of these adverse...

Cite
Klein A, Marquis-Favre C, Champelovier P. Assessment of annoyance due to urban road traffic noise combined with tramway noise. J Acoust Soc Am. 2017;141(1):231doi: 10.1121/1.4973518.
Klein, A., Marquis-Favre, C., & Champelovier, P. (2017). Assessment of annoyance due to urban road traffic noise combined with tramway noise. The Journal of the Acoustical Society of America, 141(1), 231. https://doi.org/10.1121/1.4973518
Klein, A, et al. "Assessment of annoyance due to urban road traffic noise combined with tramway noise." The Journal of the Acoustical Society of America vol. 141,1 (2017): 231. doi: https://doi.org/10.1121/1.4973518
Klein A, Marquis-Favre C, Champelovier P. Assessment of annoyance due to urban road traffic noise combined with tramway noise. J Acoust Soc Am. 2017 Jan;141(1):231. doi: 10.1121/1.4973518. PMID: 28147615.
Copy Download .nbib Format: NLM
Correction: Combined inhibition of PI3K and Src kinases demonstrates synergistic therapeutic efficacy in clear-cell renal carcinoma.

Oncotarget

Caroline R, Sofia G, Catherine P, Remi B, Pierre C, Olivier B, Laurent G, Valentin A, Claude C, Odile F.
PMID: 31040915
Oncotarget. 2019 Mar 15;10(22):2236. doi: 10.18632/oncotarget.26807. eCollection 2019 Mar 15.

[This corrects the article DOI: 10.18632/oncotarget.25700.].

Cite
Caroline R, Sofia G, Catherine P, et al. Correction: Combined inhibition of PI3K and Src kinases demonstrates synergistic therapeutic efficacy in clear-cell renal carcinoma. Oncotarget. 2019;10(22):2236doi: 10.18632/oncotarget.26807.
Caroline, R., Sofia, G., Catherine, P., Remi, B., Pierre, C., Olivier, B., Laurent, G., Valentin, A., Claude, C., & Odile, F. (2019). Correction: Combined inhibition of PI3K and Src kinases demonstrates synergistic therapeutic efficacy in clear-cell renal carcinoma. Oncotarget, 10(22), 2236. https://doi.org/10.18632/oncotarget.26807
Caroline, Roelants, et al. "Correction: Combined inhibition of PI3K and Src kinases demonstrates synergistic therapeutic efficacy in clear-cell renal carcinoma." Oncotarget vol. 10,22 (2019): 2236. doi: https://doi.org/10.18632/oncotarget.26807
Caroline R, Sofia G, Catherine P, Remi B, Pierre C, Olivier B, Laurent G, Valentin A, Claude C, Odile F. Correction: Combined inhibition of PI3K and Src kinases demonstrates synergistic therapeutic efficacy in clear-cell renal carcinoma. Oncotarget. 2019 Mar 15;10(22):2236. doi: 10.18632/oncotarget.26807. eCollection 2019 Mar 15. PMID: 31040915; PMCID: PMC6481339.
Copy Download .nbib Format: NLM
Effects of Tumor Necrosis Factor-α (TNFα) and Interferon-γ (IFNγ) on Gene Expression Profiles in Bladder Carcinoma Cells Using Oligonucleotide Microarray Analysis.

Cancer genomics & proteomics

Champelovier P, Atifi ME, Mantel F, Michallat S, Simon A, Rostaing B, Berger F, Seigneurin D.
PMID: 31394635
Cancer Genomics Proteomics. 2004 Sep-Dec;1(5):455-464. Epub 2004 Sep 01.

BACKGROUND: TNFα and IFNγ, two main cytokines secreted in the urine of bladder cancer patients after Bacillus Calmette Guerin immunotherapy (BCG therapy), exert various responses ranging from growth arrest, apoptosis, phenotypic changes and differentiation.MATERIALS AND METHODS: To identify their...

Cite
Champelovier P, Atifi ME, Mantel F, et al. Effects of Tumor Necrosis Factor-α (TNFα) and Interferon-γ (IFNγ) on Gene Expression Profiles in Bladder Carcinoma Cells Using Oligonucleotide Microarray Analysis. Cancer Genomics Proteomics. 2004;1(5):455-464
Champelovier, P., Atifi, M. E., Mantel, F., Michallat, S., Simon, A., Rostaing, B., Berger, F., & Seigneurin, D. (2004). Effects of Tumor Necrosis Factor-α (TNFα) and Interferon-γ (IFNγ) on Gene Expression Profiles in Bladder Carcinoma Cells Using Oligonucleotide Microarray Analysis. Cancer genomics & proteomics, 1(5), 455-464.
Champelovier, Pierre, et al. "Effects of Tumor Necrosis Factor-α (TNFα) and Interferon-γ (IFNγ) on Gene Expression Profiles in Bladder Carcinoma Cells Using Oligonucleotide Microarray Analysis." Cancer genomics & proteomics vol. 1,5 (2004): 455-464.
Champelovier P, Atifi ME, Mantel F, Michallat S, Simon A, Rostaing B, Berger F, Seigneurin D. Effects of Tumor Necrosis Factor-α (TNFα) and Interferon-γ (IFNγ) on Gene Expression Profiles in Bladder Carcinoma Cells Using Oligonucleotide Microarray Analysis. Cancer Genomics Proteomics. 2004 Sep-Dec;1(5):455-464. Epub 2004 Sep 01. PMID: 31394635.
Copy Download .nbib Format: NLM
Combined inhibition of PI3K and Src kinases demonstrates synergistic therapeutic efficacy in clear-cell renal carcinoma.

Oncotarget

Roelants C, Giacosa S, Pillet C, Bussat R, Champelovier P, Bastien O, Guyon L, Arnoux V, Cochet C, Filhol O.
PMID: 30046388
Oncotarget. 2018 Jul 10;9(53):30066-30078. doi: 10.18632/oncotarget.25700. eCollection 2018 Jul 10.

Potent inhibitors of PI3K (GDC-0941) and Src (Saracatinib) exhibit as individual agents, excellent oral anticancer activity in preclinical models and have entered phase II clinical trials in various cancers. We found that PI3K and Src kinases are dysregulated in...

Cite
Roelants C, Giacosa S, Pillet C, et al. Combined inhibition of PI3K and Src kinases demonstrates synergistic therapeutic efficacy in clear-cell renal carcinoma. Oncotarget. 2018;9(53):30066-30078doi: 10.18632/oncotarget.25700.
Roelants, C., Giacosa, S., Pillet, C., Bussat, R., Champelovier, P., Bastien, O., Guyon, L., Arnoux, V., Cochet, C., & Filhol, O. (2018). Combined inhibition of PI3K and Src kinases demonstrates synergistic therapeutic efficacy in clear-cell renal carcinoma. Oncotarget, 9(53), 30066-30078. https://doi.org/10.18632/oncotarget.25700
Roelants, Caroline, et al. "Combined inhibition of PI3K and Src kinases demonstrates synergistic therapeutic efficacy in clear-cell renal carcinoma." Oncotarget vol. 9,53 (2018): 30066-30078. doi: https://doi.org/10.18632/oncotarget.25700
Roelants C, Giacosa S, Pillet C, Bussat R, Champelovier P, Bastien O, Guyon L, Arnoux V, Cochet C, Filhol O. Combined inhibition of PI3K and Src kinases demonstrates synergistic therapeutic efficacy in clear-cell renal carcinoma. Oncotarget. 2018 Jul 10;9(53):30066-30078. doi: 10.18632/oncotarget.25700. eCollection 2018 Jul 10. PMID: 30046388; PMCID: PMC6059021.
Copy Download .nbib Format: NLM
A New Patient-Derived Metastatic Glioblastoma Cell Line: Characterisation and Response to Sodium Selenite Anticancer Agent.

Cancers

Berthier S, Larrouquère L, Champelovier P, Col E, Lefebvre C, Cottet-Rouselle C, Arnaud J, Garrel C, Laporte F, Boutonnat J, Faure P, Hazane-Puch F.
PMID: 30583471
Cancers (Basel). 2018 Dec 21;11(1). doi: 10.3390/cancers11010012.

Glioblastoma multiform (GBM) tumors are very heterogeneous, organized in a hierarchical pattern, including cancer stem cells (CSC), and are responsible for development, maintenance, and cancer relapse. Therefore, it is relevant to establish new GBM cell lines with CSC characteristics...

Cite
Berthier S, Larrouquère L, Champelovier P, et al. A New Patient-Derived Metastatic Glioblastoma Cell Line: Characterisation and Response to Sodium Selenite Anticancer Agent. Cancers (Basel). 2018;11(1)doi: 10.3390/cancers11010012.
Berthier, S., Larrouquère, L., Champelovier, P., Col, E., Lefebvre, C., Cottet-Rouselle, C., Arnaud, J., Garrel, C., Laporte, F., Boutonnat, J., Faure, P., & Hazane-Puch, F. (2018). A New Patient-Derived Metastatic Glioblastoma Cell Line: Characterisation and Response to Sodium Selenite Anticancer Agent. Cancers, 11(1), . https://doi.org/10.3390/cancers11010012
Berthier, Sylvie, et al. "A New Patient-Derived Metastatic Glioblastoma Cell Line: Characterisation and Response to Sodium Selenite Anticancer Agent." Cancers vol. 11,1 (2018). doi: https://doi.org/10.3390/cancers11010012
Berthier S, Larrouquère L, Champelovier P, Col E, Lefebvre C, Cottet-Rouselle C, Arnaud J, Garrel C, Laporte F, Boutonnat J, Faure P, Hazane-Puch F. A New Patient-Derived Metastatic Glioblastoma Cell Line: Characterisation and Response to Sodium Selenite Anticancer Agent. Cancers (Basel). 2018 Dec 21;11(1). doi: 10.3390/cancers11010012. PMID: 30583471; PMCID: PMC6356827.
Copy Download .nbib Format: NLM
Showing 1 to 5 of 5 entries